登录 | 注册    关注公众号  
微信公众号
搜索
 > 【NKG2D】

NKG2D信息

英文名称:NKG2-D type II integral membrane protein
中文名称
靶点别称:Killer cell lectin-like receptor subfamily K member 1,NK cell receptor D,NKG2-D-activating NK receptor,CD314,D12S2489E,KLR,DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence,Killer Cell Lectin Like Receptor K1,NKG2-D,Killer Cell Lectin-Like Receptor Subfamily K, Member 1,KLRK1,CD314 Antigen
上市药物数量:0
临床药物数量:5
最高研发阶段:临床二期

NKG2D分子别名

NKG2D,CD314,KLRK1,NK cell receptor D

NKG2D分子背景

NKG2D is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors, also known as KLRK1, CD314, D12S2489E, KLR and killer cell lectin like receptor K1. NKG2D itself forms a homodimer whose ectodomains serve for ligand binding. NKG2D is a major recognition receptor for the detection and elimination of transformed and infected cells as its ligands are induced during cellular stress, either as a result of infection or genomic stress such as in cancer. In NK cells, NKG2D serves as an activating receptor, which itself is able to trigger cytotoxicity. The function of NKG2D on CD8+ T cells is to send co-stimulatory signals to activate them.

NKG2D临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Tesnatilimab IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 临床二期 Innate Pharma 斑秃, 类风湿关节炎, 乳糜泻, 炎性疾病, 克罗恩病 详情
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) 临床二期 新型冠状病毒感染 详情
QEQ-278 QEQ-278 临床一期 Novartis Pharmaceuticals Corp 头颈部鳞状细胞癌, 肾细胞癌, 食管鳞状细胞癌, 非小细胞肺癌 详情
NKG2D CAR-T Cell therapy (Yake Biotechnology) 临床一期 上海雅科生物科技有限公司 结直肠癌, 急性髓细胞样白血病 详情
NKG2D CAR-T cell therapy (Uwell Biopharma) UWN2D 临床阶段不明 Uwell Biopharma 肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定